for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pacific Biosciences of California Inc

PACB.O

Latest Trade

20.47USD

Change

-1.09(-5.06%)

Volume

3,200,810

Today's Range

19.80

 - 

21.71

52 Week Range

17.91

 - 

53.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
21.56
Open
21.57
Volume
3,200,810
3M AVG Volume
40.92
Today's High
21.71
Today's Low
19.80
52 Week High
53.69
52 Week Low
17.91
Shares Out (MIL)
220.60
Market Cap (MIL)
4,756.10
Forward P/E
-25.36
Dividend (Yield %)
--

Next Event

Q4 2021 Pacific Biosciences of California Inc Earnings Release

Latest Developments

More

PacBio Reports Q3 2021 Financial Results

Pacific Biosciences Of California Reports Q2 2021 Financial Results

Pacific Biosciences And Invitae Announce Intent To Expand Collaboration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company has developed its Single Molecule, Real-Time (SMRT) technology, which enables single molecule, real-time detection of nucleic acid sequences, to address many of the limitations of previous sequencing technologies. The Company’s products include the Sequel II and Sequel IIe instruments and SMRT Cell 8M, which together are capable of sequencing up to approximately eight million deoxyribonucleic acid (DNA) molecules simultaneously, and the previous generation Sequel instrument and Sequel SMRT Cell 1M, which together are capable of sequencing up to one million DNA molecules simultaneously. Its Sequel IIe System increases computational capacity and is designed to enable customers to generate PacBio HiFi reads.

Industry

Medical Equipment & Supplies

Contact Info

1305 O'brien Drive

MENLO PARK, CA

94025

United States

+1.650.5218000

https://www.pacb.com/

Executive Leadership

John F. Milligan

Independent Chairman of the Board

Christian O. Henry

President, Chief Executive Officer, Director

Susan G Kim

Chief Financial Officer

Mark Van Oene

Chief Operating Officer

Catherine Ball

Senior Vice President of Research

Key Stats

2.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-0.760

2019

-0.550

2020

0.170

2021(E)

-0.850
Price To Earnings (TTM)
--
Price To Sales (TTM)
39.10
Price To Book (MRQ)
5.66
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
106.55
LT Debt To Equity (MRQ)
106.55
Return on Investment (TTM)
-3.44
Return on Equity (TTM)
-3.17

Latest News

Latest News

Jury deals loss to PacBio in genetic testing patent fight with Oxford Nanopore

A jury on Wednesday dealt a loss to gene sequencing company Pacific Biosciences of California Inc (PacBio) in its patent infringement case against rival Oxford Nanopore Technologies Ltd.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up